MapLight advances ZEPHYR-2 schizophrenia trial, continues VISTA study in Alzheimer's psychosis
Release gives conflicting dates for ZEPHYR-2 and VISTA topline results; company reports $463.4 million cash position expected to fund operations through 2028.
MapLight Therapeutics reported third-quarter 2026 results on November 16, 2026, with updates on two late-stage programs for ML-007C-MA, an M1/M4 muscarinic agonist.
For schizophrenia, the company has initiated start-up activities for ZEPHYR-2, its planned Phase 3 trial, and intends to engage with the FDA at an End-of-Phase 2 meeting to discuss the registrational path forward, with topline results expected in 2028.1 This followed the Phase 2 ZEPHYR trial, which, as previously reported in July 2026, met its primary endpoint, with the 210/3 mg twice-daily dose showing a statistically significant and clinically meaningful reduction in PANSS total score compared with placebo at Week 5,1 according to the company. The release's summary section states a different timeline for this trial, saying topline results for ZEPHYR-2 are expected in the second half of 2027, a figure that conflicts with the 2028 date given in the business update section.
For Alzheimer's disease psychosis (ADP), enrollment continues in the Phase 2 VISTA trial, a randomized, double-blind, placebo-controlled study evaluating ML-007C-MA in approximately 300 participants with ADP.1 ML-007C-MA received Fast Track designation from the FDA in December 2025 for the treatment of hallucinations and delusions associated with ADP.1 Topline results from VISTA are expected in the second half of 2027,1 per the business update, though the release's summary section states VISTA results are now expected in 2028, a separate figure that contradicts the business update.
For ML-004, an autism spectrum disorder candidate, the company plans to engage with the FDA at an End-of-Phase 2 meeting to discuss the potential registrational path forward, after which it intends to evaluate development options, including potential strategic collaborations and/or funding alternatives.1
On financing, the company completed a $150 million private placement in August 2026, with proceeds expected primarily to support ML-007C-MA, including ZEPHYR-2 and VISTA, as well as working capital and other corporate purposes.1 As of September 30, 2026, cash, cash equivalents and investments were $463.4 million, which the company said it expects will be sufficient to fund continued advancement of ML-007C-MA through 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.